March 18, 2020– A new report from a respected, independent congressional advisory panel sheds light on several of the key questions surrounding the 340B drug pricing program. In its March 2020 report to Congress, the Medicare Payment Advisory Commission (MedPAC) examined whether participation in the 340B program leads to higher drug spending for Medicare patients with five … [Read more...]